Pfizer has temporarily suspended the distribution of its popular Premarin vaginal cream in India due to unspecified supply chain difficulties. This halt significantly reduces estrogen therapy options for millions of women in India, where Premarin held over 50% of the market share by units sold and 37% by value in the conjugated estrogen market.
Pfizer (PFE) has paused the distribution of its Premarin vaginal cream in India, citing unspecified supply chain issues. This is a significant event for the Indian market, as Premarin was a dominant player, accounting for over half of all sales in its treatment category and 37% of the conjugated estrogen market value. The temporary halt creates a scarcity of treatment options for millions of women dealing with menopause symptoms, potentially leading to a short-term loss of revenue and market share for Pfizer. Conversely, competitors like Torrent Pharmaceuticals, which produces the alternative Evalon, could see a short-term opportunity to capture a larger share of the market. The long-term implications for Pfizer depend on how quickly they can resolve the supply chain issues and re-enter the market, which is projected to grow significantly.